In patients with Alzheimer’s dementia, how effective is memantine compared to either cholinesterase inhibitors or placebo in reducing anxiety and psychotic symptoms?
There was some, very limited evidence that treatment with
memantine (in addition to acetylcholinesterase inhibitors) may have
a short term (6-12 weeks) beneficial effect on psychotic symptoms
(delusions and hallucinations), in patients with moderate to severe
Alzheimer's disease, compared to treatment with
acetylcholinesterase inhibitors alone. However, it was not clear
whether this effect was maintained in the longer term (results were
inconsistent at 24 weeks). No study showed any significant effect
of memantine on anxiety symptoms. No studies were identified which
compared treatment with memantine alone to treatment with
acetylcholinesterase inhibitors alone.
Larger, high quality RCTs are needed to fully assess the effects
of memantine on anxiety and psychotic symptoms in patients with